<?xml version="1.0" encoding="UTF-8"?>
<ReportSnapshot Major="1" Minor="0" Revision="1">
	<CoIDs>
		<CoID Type="RepNo">ADEF5</CoID>
		<CoID Type="CompanyName">Tissue Regenix Group PLC</CoID>
	</CoIDs>
	<Issues>
		<Issue ID="1" Type="C" Desc="Common Stock" Order="1">
			<IssueID Type="Name">Ordinary Shares</IssueID>
			<IssueID Type="Ticker">TRX</IssueID>
			<IssueID Type="CUSIP">G8887U107</IssueID>
			<IssueID Type="ISIN">GB00B5SGVL29</IssueID>
			<IssueID Type="RIC">TRX.L</IssueID>
			<IssueID Type="SEDOL">B5SGVL2</IssueID>
			<IssueID Type="DisplayRIC">TRX.L</IssueID>
			<IssueID Type="InstrumentPI">29692202</IssueID>
			<IssueID Type="QuotePI">30107121</IssueID>
			<Exchange Code="SEA" Country="GBR">SEATS (AIM Market)</Exchange>
			<MostRecentSplit Date="2010-06-29">0.2</MostRecentSplit>
		</Issue>
	</Issues>
	<CoGeneralInfo>
		<CoStatus Code="1">Active</CoStatus>
		<CoType Code="EQU">Equity Issue</CoType>
		<LastModified>2015-10-12</LastModified>
		<LatestAvailableAnnual>2015-01-31</LatestAvailableAnnual>
		<LatestAvailableInterim>2015-07-31</LatestAvailableInterim>
		<Employees LastUpdated="2015-01-31">60</Employees>
		<SharesOut Date="2015-11-11" TotalFloat="515571555.0">760124264.0</SharesOut>
		<ReportingCurrency Code="GBP">British Pounds</ReportingCurrency>
		<MostRecentExchange Date="2016-02-22">0.70681</MostRecentExchange>
	</CoGeneralInfo>
	<TextInfo>
		<Text Type="Business Summary" lastModified="2015-10-21T09:36:31">Tissue Regenix Group plc is a United Kingdom-based medical devices company. The Company is principally engaged in the exploitation of platform technologies in the field of tissue engineering and regenerative medicine. The Company has developed decellularisation (dCELL) technology, which removes DNA and other cellular material from tissue leaving an acellular scaffold which is not rejected by the patient's body. The applications of dCELL address critical clinical needs, such as wound care, vascular disease, heart valve replacement and knee repair. The Company has developed DermaPure, a human dermis product. The Company offers OrthoPure category products, including porcine meniscus products used to repair damage from tears in the meniscus knee cartilage and tendon products used for surgical reconstruction of a torn anterior cruciate ligament in the knee. In addition, the company offers CardioPure HV, a human heart valve product.</Text>
		<Text Type="Financial Summary" lastModified="2015-10-12T14:51:15">BRIEF: For the six months ended 31 July 2015, Tissue Regenix Group PLC revenues increased from L8K to L252K. Net loss increased 7% to L3.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Administrative Expenses increase of 14% to L4.4M (expense).</Text>
	</TextInfo>
	<contactInfo lastUpdated="2016-01-19T22:21:00">
		<streetAddress line="1">The Biocentre Innovation Way Heslington</streetAddress>
		<streetAddress line="2"></streetAddress>
		<streetAddress line="3"></streetAddress>
		<city>YORK</city>
		<state-region></state-region>
		<postalCode>YO10 5NY</postalCode>
		<country code="GBR">United Kingdom</country>
		<contactName></contactName>
		<contactTitle></contactTitle>
		<phone>
			<phone type="mainphone">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1904</city-areacode>
				<number>567609</number>
			</phone>
			<phone type="mainfax">
				<countryPhoneCode>44</countryPhoneCode>
				<city-areacode>1904</city-areacode>
				<number>380517</number>
			</phone>
		</phone>
	</contactInfo>
	<webLinks lastUpdated="2012-06-14T06:18:35"><webSite mainCategory="Home Page">http://www.tissueregenix.com/</webSite><eMail mainCategory="Company Contact/E-mail">enquiries@tissueregenix.com</eMail></webLinks>
	<peerInfo lastUpdated="2016-01-19T22:21:00">
		<IndustryInfo>
			<Industry type="TRBC" order="1" reported="0" code="5620201010" mnem="">Biotechnology &amp; Medical Research - NEC</Industry>
			<Industry type="NAICS" order="1" reported="0" code="54171" mnem="">Research and Development in the Physical, Engineering, and Life Sciences</Industry>
			<Industry type="NAICS" order="2" reported="0" code="339112" mnem="">Surgical and Medical Instrument Manufacturing</Industry>
			<Industry type="NAICS" order="3" reported="0" code="51121" mnem="">Software Publishers</Industry>
			<Industry type="NAICS" order="4" reported="0" code="551112" mnem="">Offices of  Other Holding Companies</Industry>
			<Industry type="SIC" order="1" reported="0" code="8731" mnem="">Commercial Physical Research</Industry>
			<Industry type="SIC" order="2" reported="0" code="3841" mnem="">Surgical And Medical Instruments</Industry>
			<Industry type="SIC" order="3" reported="0" code="7372" mnem="">Prepackaged Software</Industry>
			<Industry type="SIC" order="4" reported="0" code="6719" mnem="">Holding Companies, Nec</Industry>
		</IndustryInfo>
	</peerInfo>
	<officers>
		<officer rank="1" since="06/09/2010">
			<firstName>John</firstName>
			<mI></mI>
			<lastName>Samuel</lastName>
			<age></age>
			<title startYear="2010" startMonth="06" startDay="29" iD1="CHM" abbr1="Chmn." iD2="DRC" abbr2="Dir.">Executive Chairman of the Board</title>
		</officer>
		<officer rank="2" since="10/2008">
			<firstName>Antony</firstName>
			<mI></mI>
			<lastName>Odell</lastName>
			<age></age>
			<title startYear="2008" startMonth="10" startDay="" iD1="CEO" abbr1="CEO" iD2="" abbr2="">Chief Executive Officer</title>
		</officer>
		<officer rank="3" since="06/13/2011">
			<firstName>Ian</firstName>
			<mI>David</mI>
			<lastName>Jefferson</lastName>
			<age>43 </age>
			<title startYear="2011" startMonth="12" startDay="" iD1="CFO" abbr1="CFO" iD2="SEC" abbr2="Secy.">Chief Financial Officer, Company Secretary, Executive Director</title>
		</officer>
	</officers>
	<Ratios PriceCurrency="GBP" ReportingCurrency="GBP" ExchangeRate="1.00000" LatestAvailableDate="2015-01-31">
		<Group ID="Price and Volume">
			<Ratio FieldName="NPRICE" Type="N">0.16000</Ratio>
			<Ratio FieldName="NHIG" Type="N">0.22490</Ratio>
			<Ratio FieldName="NLOW" Type="N">0.12700</Ratio>
			<Ratio FieldName="PDATE" Type="D">2016-02-23T00:00:00</Ratio>
			<Ratio FieldName="VOL10DAVG" Type="N">0.25007</Ratio>
			<Ratio FieldName="EV" Type="N">111.36290</Ratio>
		</Group>
		<Group ID="Income Statement">
			<Ratio FieldName="MKTCAP" Type="N">121.61990</Ratio>
			<Ratio FieldName="AREV" Type="N">0.10000</Ratio>
			<Ratio FieldName="AEBITD" Type="N">-8.19100</Ratio>
			<Ratio FieldName="ANIAC" Type="N">-7.58100</Ratio>
		</Group>
		<Group ID="Per share data">
			<Ratio FieldName="AEPSXCLXOR" Type="N">-0.01190</Ratio>
			<Ratio FieldName="AREVPS" Type="N">0.00016</Ratio>
			<Ratio FieldName="ABVPS" Type="N">0.01770</Ratio>
			<Ratio FieldName="ACSHPS" Type="N">0.01568</Ratio>
			<Ratio FieldName="ACFSHR" Type="N">-0.01167</Ratio>
			<Ratio FieldName="ADIVSHR" Type="N">0.00000</Ratio>
		</Group>
		<Group ID="Other Ratios">
			<Ratio FieldName="AGROSMGN" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="AROEPCT" Type="N">-49.62037</Ratio>
			<Ratio FieldName="APR2REV" Type="N">1216.19900</Ratio>
			<Ratio FieldName="APEEXCLXOR" Type="N">-99999.99000</Ratio>
			<Ratio FieldName="APRICE2BK" Type="N">9.03953</Ratio>
			<Ratio FieldName="Employees" Type="N">60</Ratio>
		</Group>
	</Ratios>
	<ForecastData ConsensusType="Mean" CurFiscalYear="2016" CurFiscalYearEndMonth="1" CurInterimEndCalYear="2016" CurInterimEndMonth="1" EarningsBasis="PRX">
		<Ratio FieldName="ConsRecom" Type="N">
			<Value PeriodType="CURR">1.5</Value>
		</Ratio>
		<Ratio FieldName="TargetPrice" Type="N">
			<Value PeriodType="CURR">0.36000</Value>
		</Ratio>
		<Ratio FieldName="ProjLTGrowthRate" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjPE" Type="N">
			<Value PeriodType="CURR">-10.38961</Value>
		</Ratio>
		<Ratio FieldName="ProjSales" Type="N">
			<Value PeriodType="CURR">1.28900</Value>
		</Ratio>
		<Ratio FieldName="ProjSalesQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjEPS" Type="N">
			<Value PeriodType="CURR">-0.01540</Value>
		</Ratio>
		<Ratio FieldName="ProjEPSQ" Type="N">
			<Value PeriodType="CURR">-99999.99000</Value>
		</Ratio>
		<Ratio FieldName="ProjProfit" Type="N">
			<Value PeriodType="CURR">-10.19500</Value>
		</Ratio>
		<Ratio FieldName="ProjDPS" Type="N">
			<Value PeriodType="CURR">0.00000</Value>
		</Ratio>
	</ForecastData>
</ReportSnapshot>
